Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term safety study of ZOC2019619 eye drops in primary open-angle glaucoma or ocular hypertension
CTR20262896Phase 3Active
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Jul 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ZOC2019619 in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Incidence of treatment-emergent adverse events and drug-related adverse events. Started Jul 2026; status: active.
02
Drugs
ZOC2019619
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on CTR20262896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262896.